home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why Shares of 89bio Plummeted on Tuesday ↗

October 10, 2023

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

Via The Motley Fool

Akero Therapeutics' Disappointing NASH Data Drags Its Rival ↗

October 10, 2023

Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to

Via Benzinga

Crude Oil Moves Lower; Neogen Posts Downbeat Results ↗

October 10, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500...

Via Benzinga

Topics Stocks

Big Pharma Could Transform Into BioTech Pharma ↗

October 10, 2023

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 10, 2023

Via Benzinga

4 Analysts Have This to Say About Akero Therapeutics ↗

September 19, 2023

Via Benzinga

Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 10, 2023

Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.

Via Benzinga

S&P 500 Rises 1%; US Wholesale Inventories Fall In August ↗

October 10, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Akero Therapeutics Stock Is Crashing Today ↗

October 10, 2023

Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).

Via The Motley Fool

PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday ↗

October 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today? ↗

October 10, 2023

Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to

Via Benzinga

Why Is Ocugen (OCGN) Stock Up 5% Today? ↗

October 10, 2023

Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine.

Via InvestorPlace

NET Stock Alert: Cloudflare Discovers New Cyber Vulnerability ↗

October 10, 2023

Cloudflare stock is getting a boost on Tuesday as investors in NET react to the cybersecurity company discovering a new vulnerability.

Via InvestorPlace

US Stocks Gain; PepsiCo Posts Upbeat Earnings ↗

October 10, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...

Via Benzinga

Topics Stocks

Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? ↗

October 10, 2023

Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.

Via InvestorPlace

Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio ↗

October 10, 2023

Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 10, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

October 10, 2023

It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning!

Via InvestorPlace

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and

October 10, 2023

From Akero Therapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 09, 2023

Via Benzinga

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

October 09, 2023

Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology

October 04, 2023

From Akero Therapeutics

Via GlobeNewswire

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023 ↗

September 19, 2023

Via Benzinga

Akero Therapeutics to Present at Upcoming Healthcare Conferences in September

August 31, 2023

From Akero Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023 ↗

August 28, 2023

Via Benzinga

Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023

August 28, 2023

From Akero Therapeutics

Via GlobeNewswire

Over $15.5M Bet On ModivCare? Check Out These 4 Stocks Insiders Are Buying ↗

August 11, 2023

Although U.S. stocks closed slightly higher on Thursday, there were a few notable insider trades.

Via Benzinga

Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 11, 2023

From Akero Therapeutics

Via GlobeNewswire

Over $2M Bet On Akero Therapeutics? Check Out These 3 Stocks Insiders Are Buying ↗

August 02, 2023

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com